Dexcom Inc. Stock
Dexcom Inc. Stock
Dexcom Inc. dominated the market today, gaining €3.60 (5.680%).
With 44 Buy predictions and 2 Sell predictions Dexcom Inc. is one of the favorites of our community.
As a result the target price of 73 € shows a slightly positive potential of 8.96% compared to the current price of 67.0 € for Dexcom Inc..
For the coming years our community has positive and negative things to say abot the Dexcom Inc. stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "General Risks" there were negative voices in the community.
Pros and Cons of Dexcom Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Dexcom Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Dexcom Inc. | 5.680% | 0.000% | 23.346% | -16.623% | 10.607% | -45.969% | -19.415% |
| Baxter International | -0.890% | 4.282% | 16.298% | -36.236% | 3.149% | -56.123% | -75.133% |
| Teleflex Inc. | 0.620% | 2.450% | 8.142% | 7.524% | 10.686% | -47.731% | -64.272% |
| Dentsply Sirona Inc. | 0.440% | -3.146% | -8.495% | -37.986% | -9.468% | -76.109% | -84.058% |
Comments
DexCom (DXCM) was given a new $90.00 price target by Stifel Nicolaus. They now have a "buy" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (DXCM) had its "buy" rating reaffirmed by Citigroup Inc..
Show more
Ratings data for DXCM provided by MarketBeat
DexCom (DXCM) had its price target lowered by Bank of America Corporation from $100.00 to $80.00. They now have a "buy" rating on the stock.
Show more
Ratings data for DXCM provided by MarketBeat
News
DexCom vs. Insulet: Which Diabetes Stock Is a Better Buy in 2026?
Diabetes management is evolving rapidly as the industry innovates to treat the more than 40 million Americans with type 1 or type 2 diabetes. Deciding between two leaders in monitoring and
DexCom Maps G8 Launch, Coverage Expansion and Double-Digit Growth at Investor Day
DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for
Pediatrix Medical Group Q1 Earnings Call Highlights
Pediatrix Medical Group (NYSE:MD) reaffirmed its full-year 2026 adjusted EBITDA outlook after reporting what management described as a strong first quarter, supported